Sugi Predict

Sugi Predict / Compounds / SCHEMBL678160

SCHEMBL678160

SCHEMBL678160

CN[C@H]1C[C@H](C)S(=O)(=O)c2sc(S(N)(=O)=O)cc21

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
▸ CA2 P00918 18/20 1.00
▸ CA1 P00915 4/20 0.77
▸ CA12 O43570 1/20 0.77
▸ CA3 P07451 1/20 0.77
▸ AR P10275 1/20 0.77
▸ CA4 P22748 1/20 0.77
▸ CA6 P23280 1/20 0.77
▸ CA5A P35218 1/20 0.77
▸ CA7 P43166 1/20 0.77
▸ CA9 Q16790 1/20 0.77
▸ CA13 Q8N1Q1 1/20 0.77
▸ CA14 Q9ULX7 1/20 0.77
▸ CA5B Q9Y2D0 1/20 0.77
▸ LMNA P02545 1/20 0.77
▸ TSHR P16473 1/20 0.77

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22372488 1.00 CA2 (1.00) CA2CA1CA12CA3AR
SCHEMBL9525726 1.00 CA2 (1.00) CA2CA1CA12CA3AR
Dorzolamide SCHEMBL12874119 0.87 CA2 (1.00) CA2CA1CA12CA3AR
Dorzolamide SCHEMBL9914275 0.87 CA2 (1.00) CA2CA1CA12CA3AR
Dorzolamide SCHEMBL4525137 0.87 CA2 (1.00) CA2CA1CA12CA3AR
Dorzolamide SCHEMBL4455530 0.87 CA2 (1.00) CA2CA1CA12CA3AR
Dorzolamide SCHEMBL12223216 0.87 CA2 (1.00) CA2CA1CA12CA3AR
Dorzolamide SCHEMBL3306381 0.87 CA2 (1.00) CA2CA1CA12CA3AR
Dorzolamide SCHEMBL9914274 0.87 CA2 (1.00) CA2CA1CA12CA3AR
Dorzolamide SCHEMBL24061 0.87 CA2 (1.00) CA2CA1CA12CA3AR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 54 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210254056-A1 IDENTIFICATION AND TARGETED MODULATION OF GENE SIGNALING NETWORKS CAMP4 THERAPEUTICS CORPORATION 2021-08-19 — — US disclosed
US-10877035-B2 Advanced drug development and manufacturing ICAGEN, LLC (US) 2020-12-29 — — US disclosed
US-20190192691-A1 REGULATED BIOCIRCUIT SYSTEMS OBSIDIAN THERAPEUTICS, INC. 2019-06-27 — — US disclosed
US-9956302-B2 Compounds and compositions for the treatment of ocular disorders Graybug Vision, Inc. (US) 2018-05-01 — — US disclosed
US-9956302-B2 Compounds and compositions for the treatment of ocular disorders Graybug Vision, Inc. (US) 2018-05-01 — — US disclosed
US-20150309021-A1 Advanced Drug Development and Manufacturing LOS ALAMOS NATIONAL SECURITY, LLC 2015-10-29 — — US disclosed
EP-2511844-B1 X-ray microscope XRPRO SCIENCES INC (US) 2015-08-12 — — EP disclosed
EP-2511844-A2 Advanced drug development and manufacturing Los Alamos National Security, LLC (US) 2012-10-17 — — EP disclosed
EP-2084519-B1 X-RAY FLUORESCENCE ANALYSIS METHOD LOS ALAMOS NAT SECURITY LLC (US) 2012-08-01 — — EP disclosed
US-20110269717-A1 NEUROGENESIS BY MODULATING ANGIOTENSIN BRAINCELLS INC. (US) 2011-11-03 — — US disclosed
WO-2008030651-A1 COMBINATIONS CONTAINING A 4-ACYLAMINOPYRIDINE DERIVATIVE BRAINCELLS, INC. (US) 2008-03-13 — — WO disclosed
US-20080064671-A1 COMBINATIONS CONTAINING A 4-ACYLAMINOPYRIDINE DERIVATIVE BRAINCELLS, INC. (US) 2008-03-13 — — US disclosed
WO-2007134136-A2 NEUROGENESIS BY MODULATING ANGIOTENSIN BRAINCELLS, INC. (US) 2007-11-22 — — WO disclosed
WO-2007134077-A2 5 HT RECEPTOR MEDIATED NEUROGENESIS BRAINCELLS, INC. (US) 2007-11-22 — — WO disclosed
US-20070270449-A1 5 HT RECEPTOR MEDIATED NEUROGENESIS BRAINCELLS, INC. (US) 2007-11-22 — — US disclosed
WO-2007104035-A1 MODULATION OF NEUROGENESIS BY NOOTROPIC AGENTS BRAINCELLS, INC. (US) 2007-09-13 — — WO disclosed
US-20070112017-A1 GABA RECEPTOR MEDIATED MODULATION OF NEUROGENESIS BRAINCELLS, INC. (US) 2007-05-17 — — US disclosed
WO-2007053596-A1 GABA RECEPTOR MEDIATED MODULATION OF NEUROGENESIS BRAINCELLS, INC. (US) 2007-05-10 — — WO disclosed
WO-2007047978-A2 MODULATION OF NEUROGENESIS BY PDE INHIBITION BRAINCELLS, INC. (US) 2007-04-26 — — WO disclosed
US-20070078083-A1 MODULATION OF NEUORGENESIS BY HDac INHIBITION BRAINCELLS, INC. (US) 2007-04-05 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070112017-A1 GABA RECEPTOR MEDIATED MODULATION OF NEUROGENESIS GABRB2, GAP43, GABRB1 CA2 1899/4885CA1 1505/4885CA12 3830/4885
US-20070270449-A1 5 HT RECEPTOR MEDIATED NEUROGENESIS HTR5A, HTR6, GAP43 CA2 4254/4885CA1 3774/4885CA12 4768/4885
US-20070078083-A1 MODULATION OF NEUORGENESIS BY HDac INHIBITION DCX, BDNF, NTRK2 CA2 2317/4885CA1 1159/4885CA12 3188/4885
US-20110269717-A1 NEUROGENESIS BY MODULATING ANGIOTENSIN NGF, DCX, BDNF CA2 729/4885CA1 1075/4885CA12 2751/4885
US-20080064671-A1 COMBINATIONS CONTAINING A 4-ACYLAMINOPYRIDINE DERIVATIVE GRIN2C, COQ8A, GRIN2D CA2 2390/4885CA1 2214/4885CA12 3572/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.